Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.69 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.64 |
| ▸ | MGLL | Q99685 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750537 | 0.82 | FAAH (0.86) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL381113 | 0.78 | FAAH (0.57) | FAAHDRD2DRD3KCNH2 | |
| Urb-597 SCHEMBL93842 | 0.78 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| Urb-597 SCHEMBL29371698 | 0.78 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089400 | 0.77 | FAAH (0.84) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14187855 | 0.77 | FAAH (0.98) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL17175654 | 0.75 | FAAH (0.93) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL12803599 | 0.74 | FAAH (0.73) | FAAHDRD2DRD3KCNH2 | |
| SCHEMBL4183181 | 0.74 | FAAH (0.71) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14044821 | 0.74 | FAAH (0.67) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-10-04 | — | — | US | claimed |
| EP-2408743-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | claimed |
| WO-2010105930-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252865-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ACHE, CHRNA10, CHRNA5 | FAAH 151/4885TRPA1 182/4885EPHX2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.